Malcolm K Brenner
Overview
Explore the profile of Malcolm K Brenner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
16801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li C, Sharma S, Heczey A, Woods M, Steffin D, Louis C, et al.
Nat Med
. 2025 Feb;
PMID: 39962287
In a phase 1 clinical trial open to accrual from 2004 to 2009, we treated children with neuroblastoma with Epstein-Barr virus (EBV)-specific T lymphocytes and CD3-activated T cells-each expressing chimeric...
2.
Rao X, Tseng M, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson T, et al.
Cancer Gene Ther
. 2024 Dec;
32(1):147.
PMID: 39633010
No abstract available.
3.
Rosewell Shaw A, Morita D, Porter C, Tu E, Biegert G, Agrawal S, et al.
Mol Ther Oncol
. 2024 Dec;
32(4):200899.
PMID: 39624055
Systemic administration of oncolytic viruses (OVs) is a promising approach for targeting metastatic solid tumors, but their anti-tumor activity is limited by pre-existing neutralizing antibodies against common human viruses. Therefore,...
4.
Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney A, Arnett A, et al.
Nature
. 2024 Nov;
637(8047):940-946.
PMID: 39604730
Interleukin-15 (IL-15) promotes the survival of T lymphocytes and enhances the antitumour properties of chimeric antigen receptor (CAR) T cells in preclinical models of solid neoplasms in which CAR T ...
5.
Ozcan A, Aquino Lopez A, Wolff A, Ma A, Rosewell Shaw A, Suzuki M, et al.
Mol Ther Methods Clin Dev
. 2024 Jul;
32(3):101279.
PMID: 38993326
Systemic delivery of oncolytic and immunomodulatory adenoviruses may be required for optimal effects on human malignancies. Mesenchymal stromal cells (MSCs) can serve as delivery systems for cancer therapeutics due to...
6.
Ma R, Woods M, Burkhardt P, Crooks N, van Leeuwen D, Shmidt D, et al.
Cell Rep Med
. 2024 Jul;
5(7):101628.
PMID: 38986621
Chimeric antigen receptor T cells (CART) targeting lymphocyte antigens can induce T cell fratricide and require additional engineering to mitigate self-damage. We demonstrate that the expression of a chimeric antigen...
7.
Al Hadidi S, Heslop H, Brenner M, Suzuki M
Mol Ther
. 2024 Jun;
32(8):2444-2460.
PMID: 38822527
In recent years, the therapeutic landscape for hematological malignancies has markedly advanced, particularly since the inaugural approval of autologous chimeric antigen receptor T cell (CAR-T) therapy in 2017 for relapsed/refractory...
8.
Lin F, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, et al.
J Clin Oncol
. 2024 May;
42(23):2769-2779.
PMID: 38771986
Purpose: T cells modified with chimeric antigen receptors (CARTs) have demonstrated efficacy for hematologic malignancies; however, benefit for patients with CNS tumors has been limited. To enhance T cell activity...
9.
Che-Hsing L, Sharma S, Heczey A, Steffin D, Louis C, Grilley B, et al.
Res Sq
. 2024 Apr;
PMID: 38659815
We report long-term outcomes up to 18 years of a clinical trial treating children with neuroblastoma with EBV-specific T lymphocytes and CD3-activated T cells - each expressing a first-generation chimeric...
10.
Hegde M, Navai S, DeRenzo C, Joseph S, Sanber K, Wu M, et al.
Nat Cancer
. 2024 Apr;
5(6):880-894.
PMID: 38658775
In this prospective, interventional phase 1 study for individuals with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells) after lymphodepletion with fludarabine (Flu)...